CEPI to provide funding of up to US$3.6 million to advance the development of Gennova Biopharmaceutical’s self-amplifying thermostable mRNA vaccine platform to develop vaccine candidates against Disease X. • Funding will support optimisation of the technology platform to enhance immunogenicity. 8 August 2023, OSLO Norway: The Coalition for Epidemic
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support Availability of a toll-free help line number 1800 103 4260 to provide coordination & counselling support for patients The initiative aims to drive HAE awareness through patient education, and timely
Takeda Biopharmaceuticals India Private Limited (formerly known as Baxalta Bioscience India Pvt. Ltd.), a global values-based, R&D-driven biopharmaceutical leader, has been certified as a Great Place To Work® in India (March 2023 - March 2024). This certification has been awarded second time in a row to
Takeda Biopharmaceuticals India Private Limited Showcased Digital Innovations- MyPKFit, SYNAPSE and Athena at the G20 Health Working Group Meeting The Three-Day Meeting was Held in Goa, India, from April 17th to April 19th, 2023, and Side Event was Focused on: ‘Citizen-Centric Health Delivery Ecosystems
CINRYZE™ is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE. Among adult HAE patients, 51% miss at least one day of work (mean 3.3 days), 44% students miss at least one day of school
Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaningful benefits of dapagliflozin in patients with heart failure regardless of ejection fraction Heart failure is a chronic, progressive disease impacting nearly 64
